27 studies on Glucagon receptor mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This completed Phase II study for BI 456906 is a crucial step in developing new treatments for Type 2 Diabetes Mellitus and obesity. If positive, the findings could identify optimal dosing strategies for a novel compo…
The introduction of resmetirom and the proven efficacy of semaglutide represent a revolutionary shift in the treatment paradigm for MASH, moving beyond solely lifestyle interventions. These drugs offer the first speci…
Establishing bioequivalence between different drug formulations is crucial for drug development. It ensures that any changes in formulation (e.g., for improved stability, manufacturing, or patient convenience) do not …
If the results demonstrate significant efficacy, survodutide could represent a transformative new therapeutic option for individuals struggling with the dual burden of overweight/obesity and Type 2 Diabetes. As a dual…
This RANDOMIZED, QUADRUPLE, TREATMENT trial is currently RECRUITING participants, with an estimated completion in December 2028, meaning no results are available yet. The study is meticulously designed to investigate …
The successful outcome of this Phase III trial could represent a significant advancement in the treatment of overweight and obesity, particularly for the Chinese population, where specific therapeutic options are high…
This detailed trial design and baseline data publication is crucial as it lays the groundwork for understanding the potential of Mazdutide as a significant new therapeutic option. If Mazdutide demonstrates superior or…
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
Understanding the baseline characteristics of participants in a large Phase 3 trial is crucial for interpreting the future efficacy and safety results, ensuring the findings are generalizable to the target patient pop…
This research boldly underscores the critical role of hepatic GCGR in mediating the profound metabolic benefits of dual GLP-1R/GCGR agonists like survodutide. Understanding this mechanism could lead to the development…
This research provides crucial insights into the central mechanism of action for Survodutide, demonstrating its direct engagement with brain regions critical for appetite regulation. Understanding that Survodutide act…
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
This study highlights Survodutide's potential as a groundbreaking treatment for obesity and MASH, leveraging a dual mechanism of action through GLP-1 and glucagon receptor agonism. Its ability to induce substantial we…
This research provides compelling evidence that alpha-cell dysregulation and subsequent hyperglucagonemia play a central, previously underappreciated role in the development of diabetic cardiomyopathy. By demonstratin…
This study highlights the critical importance of considering sex as a biological variable in metabolic research and drug development. The enhanced FGF21 response and profound metabolic improvements observed specifical…
The initiation of this large-scale clinical trial for Retatrutide is a pivotal step towards addressing the interconnected epidemics of Type 2 Diabetes and obesity with a single, highly potent therapeutic agent. If suc…
This comprehensive meta-analysis provides strong evidence supporting retatrutide's exceptional efficacy and acceptable safety profile, positioning it as a highly promising therapeutic option for individuals with obesi…
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
This review underscores the critical importance of understanding glucagon's pleiotropic (multiple) actions beyond glucose regulation. By elucidating shared mechanistic pathways, it provides a robust scientific rationa…
This review underscores the transformative potential of novel GLP-1-based medications to significantly advance the treatment of Type 2 Diabetes and Obesity. The enhanced efficacy in weight loss and glycemic control, c…
This network meta-analysis provides crucial comparative data on the efficacy and safety of various Glucagon Receptor Agonists, offering a more nuanced understanding than individual trials alone. The findings can help …